The product is used to help provide symptomatic relief and supportive benefit across key therapeutic domains, particularly in contexts marked by increased discomfort or tension during episodes. It is applied within therapeutic domains where short-term symptom management is appropriate, such as in cases requiring temporary symptomatic assistance across common symptom clusters. Within these contexts, such products are generally relevant for easing temporary discomfort.

Easing Pronounced and Disruptive Symptoms

Night Rest helps address symptom clusters that may become intense or disruptive and are relevant for managing symptoms that interfere with daily comfort. It is commonly used to help with symptoms related to physical discomfort that create noticeable physiological strain, and may assist with maintaining functional stability while contributing to easing the overall symptom load during symptomatic phases. The product is relevant for situations involving symptomatic discomfort, heightened physiological activity, and localized irritative states.

Support in Acute Symptomatic Episodes

It is commonly used during phases when symptoms become more noticeable, particularly in conditions characterized by periods of heightened symptoms or episodic manifestations. The product provides supportive relief when short-term symptomatic assistance is needed and contributes to improved comfort during periods of temporary physiological imbalance.

Quick Fact: Support for Acute Discomfort

Regulatory References

1. Health Canada Labelling Standard

Who can and cannot use Night Rest?

Eligibility for Night Rest (Valeriana officinalis root extract) is defined by official regulatory documentation, primarily based on age and physiological state. The information below reflects formal classifications regarding who is permitted to use the product and who is excluded.

Approved and Restricted Populations

Classification	Population Eligibility Status (Official Labeling)
Permitted Use	Adults and adolescents over 12 years of age. Use is established based on traditional herbal medicinal product monographs.
Contraindicated	Individuals with a known hypersensitivity or allergy to Valeriana officinalis or any of the inactive ingredients.
Not Recommended	Children under 12 years of age. Safety has not been established due to insufficient data.
Not Recommended	Women who are pregnant or breastfeeding. Use is restricted due to a lack of sufficient safety data.

Conditional Eligibility

While not formal contraindications, caution is advised for patients with severe hepatic impairment or severe renal impairment who should seek guidance before use. Official eligibility rules focus strictly on the populations listed above and do not cross into prescribing instructions, mechanisms of action, or treatment benefits.

The interaction profile for Night Rest (Valeriana officinalis root extract) is defined by official regulatory statements concerning both pharmacodynamic and pharmacokinetic effects. Authorities, including the European Medicines Agency, confirm that the product’s potential for interactions involving major metabolic pathways is considered not clinically relevant. Specifically, no relevant changes in systemic exposure have been observed regarding the activity of key CYP enzymes, including CYP 1A2, CYP 2D6, CYP 2E1, and CYP 3A4.

The most significant documented interaction is the risk of Pharmacodynamic Reinforcement, which involves additive central nervous system (CNS) depression. Co-administration is advised against or requires caution with any substance possessing sedative effects, including prescription synthetic sedatives such as benzodiazepines and barbiturates, as well as narcotic pain medications and muscle relaxants. This caution stems from the product's established CNS depressant effect.

Specific drug-substance restrictions are also officially noted. The product must not be taken with alcohol (ethanol), as this combination is documented to significantly increase drowsiness and enhance the sedative effect. Similar caution applies to the co-use of other sedating herbal products or supplements.

Furthermore, the official labeling includes population-specific constraints: use is not recommended for children under 12 years of age due to an absence of adequate interaction data for this demographic, and caution is advised for patients with existing liver conditions.

u1f500 Modulating the GABA A Receptor

The mechanism is centered on the positive allosteric modulation of the GABA A receptor complex, primarily via Valerenic acid. This interaction enhances the sensitivity of these inhibitory receptors to the body’s natural GABA neurotransmitter, increasing the flow of chloride ions into neurons. This key molecular step initiates the systemic reduction of neuronal excitability.

---

u1f9e0 Increasing Central Physiological Inhibition

The resulting increase in GABAergic signaling increases the overall inhibitory tone of the Central Nervous System (CNS). This generalized reduction in nerve cell firing across key brain regions results in a lower state of arousal. This mechanism regulates overactive signaling patterns, which is associated with a lower state of CNS activity.

---

Multi-Component Action and Specificity

The physiological consequence is a result of a multi-component mechanism where the core GABA A modulation is complemented by other constituents that may inhibit GABA breakdown, or influence other defined regulatory pathways, such as 5-HT1 A receptor activity. The intensity of this mechanism is chemically constrained by the concentration of Valerenic acid in the extract, tying the biological activity directly to the standardization of the active ingredients.

Administration Guidelines for Night Rest

Night Rest is an oral preparation intended for use as a botanical supplement. It is administered via the oral route as a standardized extract capsule. The usage guidelines define the procedural steps for use.

---

Administration Scope

Feature	Instruction
Route of Administration	Oral use only.
Dosing Schedule	A single dose of the 400 mg to 600 mg extract equivalent is administered once nightly.
Timing & Preparation	It is taken 30 to 60 minutes before bedtime, swallowed whole with a glass of water. It can be taken with or without food.
Age-Group Rules	The standard regimen is restricted for use in adults (18 years and older).
Course Duration	Intended for short-term symptomatic use (e.g., up to four weeks). Optimal effect may require repeated nightly administration.

---

Procedural Structure

The procedural sequence involves taking one standardized capsule nightly, ensuring it is swallowed whole without being crushed. Administration is not to exceed the once-daily frequency, and if a dose is missed, the next dose is taken as scheduled the following night. These instructions define the standardized approach to using the preparation.

Research evidence / Overview of studies for Night Rest

Evidence for Use in Occasional Sleeplessness

Research has been conducted to examine how Valeriana root extract was studied in relation to occasional sleeplessness in adults. The primary research exploring short-term symptom changes utilizes Randomized Controlled Trials (RCTs), with their findings analyzed in subsequent systematic reviews and meta-analyses. Studies explored outcomes related to perceived sleep quality and the time taken to fall asleep (sleep latency), which are patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in the studies related to subjective sleep metrics. Specifically, some trials described patterns such as a change in the time it took participants to fall asleep. However, the research highlights changes measured during the study period which were often based on self-reported feelings of restfulness, and the reported patterns of change were observed in some studies but findings were mixed across various extract preparations and study designs. Research provides insight into short-term changes, but studies do not determine whether an individual will respond similarly.

Evidence for Use in Mild Nervous Tension

The extract was studied for its use in cases of mild nervous tension and general restlessness, which are symptoms relevant in trials assessing short-term or episodic symptom patterns before bedtime. Studies were applied in research contexts involving fluctuating or unstable symptoms by observing individuals who were experiencing mild stress-related sleep disturbances. These studies monitored changes in tension scores and global assessments of improvement in symptoms that may vary in intensity.

Data show patterns related to self-reported changes in feelings of general restlessness or tension, outcomes related to systemic or functional imbalance. Studies report how symptoms evolved in the observed populations during the short-term observation windows. Research provides insight into short-term changes.

Long-Term Studies and Follow-Up

Follow-up durations were limited, typically spanning between one and four weeks in controlled studies. Therefore, there is limited information for long-term outcomes regarding the use of Valeriana root extract. The research focuses on temporary, acute episodes, and extended-duration data that would describe the durability of observed symptom patterns are not fully established. Studies observing responses over defined time intervals primarily reflect short-term experiences.

Research in Specific Populations

Most evidence has been derived from studies involving generally healthy adults experiencing occasional sleep difficulty or restlessness. The results apply only to the populations studied. Data for certain groups remain insufficient, meaning there is limited information available for specific populations, such as older adults, children, or individuals with concurrent health issues or comorbidities. Subgroup findings are uncertain, as the existing research base has not extensively focused on these specialized populations.

Evidence Gaps and Areas of Scientific Uncertainty

The research on the root extract contributes to the broader evidence landscape, but certainty remains low regarding definitive outcomes across all preparations. Evidence quality varies across studies, partly due to the use of different manufacturing processes resulting in variable extract compositions. The data are still emerging, and research is ongoing, but the field faces limitations. These include the frequent reliance on subjective measures (patient self-reports) for primary outcomes and the fact that sample sizes were modest in many individual trials. Furthermore, the overall evidence base exhibits heterogeneity, which means findings were mixed across different research groups, highlighting what is known — and what is still uncertain.

Key Studies & References Health Canada Labelling Standard for Non-prescription Oral Adult Cough, Cold, and Flu Products (Referenced for context on temporary symptomatic relief)

Common questions about Night Rest (FAQ)

Q: What is Night Rest used for?

Night Rest is officially indicated for the short-term treatment of difficulty sleeping (insomnia) in adults. According to regulatory documents, its primary use is to assist with sleep initiation, which is the time it takes to fall asleep.

Q: How quickly does Night Rest typically start to work?

Studies and official information indicate that Night Rest begins to work quickly to help with sleep initiation. The official product information notes that due to its rapid action, the medication should only be taken when a full night's sleep of 7 to 8 hours is possible.

Q: What should I do if I forget to take my dose of Night Rest?

According to the official product label, if a dose is missed, it should only be taken if a full night’s sleep (7 to 8 hours) is still achievable. Official guidance emphasizes that users should never take two doses at once and should skip the missed dose if the appropriate window has passed.

Q: Can I stop taking Night Rest suddenly?

Official documentation indicates that treatment cessation, especially after prolonged use, may require medical guidance to assess the need for gradual reduction. Stopping treatment abruptly may be associated with temporary difficulty sleeping that is slightly worse than before (rebound insomnia), as noted in the official product information.

Q: Is there a risk of becoming dependent on Night Rest?

Regulatory documents state that Night Rest has the potential for dependence, particularly with prolonged use. The risk increases if the medication is used for longer than the recommended short-term duration or at higher than prescribed doses. This is why the medication is recommended only for short-term treatment.

Q: Does Night Rest affect driving or operating machinery the next day?

Studies and official information indicate that Night Rest can potentially impair the ability to drive or operate machinery, even the day after taking it. This risk is higher if the dose is high or if a full 7 to 8 hours of sleep is not achieved. Official documentation advises caution for activities requiring full mental alertness until the user understands how the medicine affects them.

Q: What is the recommended duration for taking Night Rest?

According to the official product information, Night Rest is intended only for short-term use, typically for a period of 7 to 10 consecutive days. The overall duration of treatment, including any necessary tapering off, should usually not exceed 4 weeks. If difficulty sleeping persists beyond this duration, a healthcare provider should be consulted.

Q: What if Night Rest doesn't seem to be working for me after a few nights?

Regulatory documents state that if insomnia persists or worsens after 7 to 14 days of using Night Rest, this may signal a different underlying medical problem. If the medication is not providing adequate relief after this period, it is officially advised that the user discontinue use and seek further medical consultation. The official product information emphasizes that treatment effectiveness should be reviewed regularly by a healthcare professional.

How to Store and Dispose of Night Rest

Official labeling requires the product to be stored at room temperature, typically below 25 C (77 F), and instructs that it must be protected from excessive heat and moisture. The product should be kept in its original container, which must remain tightly closed to maintain product integrity.

To ensure child safety, the product must be stored out of the sight and reach of children, and any safety caps must be locked immediately after use.

Disposal Requirements

Unused or expired product should be disposed of by following official regulatory procedures. The preferred method is through a local drug take-back program. If one is unavailable, the product may be mixed with an unappealing substance, sealed in a bag, and then discarded in the household trash. The product must not be flushed down a toilet unless specifically directed by official guidelines.